As, we have previously reported, the number of Pradaxa lawsuits continues to grow across the country. The number of lawsuits has increased by nearly 17% in recent months and now approaches 200 nationwide.
The medication resource center, DrugRisk, continues to receive, organize and disseminate safety issues relating to Pradaxa. New reports indicate Pradaxa is more dangerous than previously thought. While the FDA issued an update that the drug carries similar risks to its generic counterpart warfarin, a new report issued by the American College of Cardiology warns that Pradaxa use can significantly increase the risk of bleeding complications compared to warfarin. The Institute for Safe Medication Practices ranked Pradaxa among the most dangerous of outpatient drugs, reporting that bleeding caused by Pradaxa is nearly 5 times more likely to result in death than its generic counterpart warfarin.
If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.